Henry Schein, Inc. (NASDAQ:HSIC) Holdings Cut by Nuance Investments LLC

Nuance Investments LLC reduced its holdings in Henry Schein, Inc. (NASDAQ:HSIC) by 13.6% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 1,969,166 shares of the company’s stock after selling 308,915 shares during the quarter. Henry Schein comprises 5.5% of Nuance Investments LLC’s investment portfolio, making the stock its 5th largest position. Nuance Investments LLC owned approximately 1.58% of Henry Schein worth $136,266,000 as of its most recent SEC filing.

Several other hedge funds have also recently made changes to their positions in HSIC. Holocene Advisors LP bought a new stake in Henry Schein in the third quarter valued at $58,319,000. Southpoint Capital Advisors LP boosted its stake in shares of Henry Schein by 30.0% during the 3rd quarter. Southpoint Capital Advisors LP now owns 2,600,000 shares of the company’s stock valued at $189,540,000 after purchasing an additional 600,000 shares in the last quarter. Healthcare of Ontario Pension Plan Trust Fund purchased a new position in shares of Henry Schein during the third quarter valued at about $43,740,000. Bank of Montreal Can raised its stake in Henry Schein by 365.6% in the third quarter. Bank of Montreal Can now owns 711,487 shares of the company’s stock worth $52,095,000 after buying an additional 558,689 shares in the last quarter. Finally, Raymond James Financial Inc. purchased a new stake in Henry Schein in the fourth quarter worth about $34,720,000. 96.62% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Henry Schein

In other Henry Schein news, CEO Bradford C. Connett sold 4,036 shares of Henry Schein stock in a transaction dated Wednesday, March 19th. The stock was sold at an average price of $71.15, for a total value of $287,161.40. Following the transaction, the chief executive officer now owns 62,688 shares in the company, valued at $4,460,251.20. The trade was a 6.05 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Philip A. Laskawy sold 2,604 shares of the stock in a transaction dated Wednesday, March 19th. The shares were sold at an average price of $71.04, for a total transaction of $184,988.16. Following the sale, the director now directly owns 24,805 shares of the company’s stock, valued at approximately $1,762,147.20. The trade was a 9.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.14% of the stock is currently owned by corporate insiders.

Henry Schein Trading Down 2.0 %

Shares of NASDAQ HSIC opened at $69.38 on Wednesday. The business’s 50 day moving average price is $74.79 and its 200-day moving average price is $72.65. Henry Schein, Inc. has a fifty-two week low of $63.67 and a fifty-two week high of $82.49. The company has a debt-to-equity ratio of 0.46, a quick ratio of 0.82 and a current ratio of 1.42. The company has a market cap of $8.62 billion, a price-to-earnings ratio of 28.55, a PEG ratio of 2.13 and a beta of 0.90.

Henry Schein (NASDAQ:HSIC) last posted its quarterly earnings results on Tuesday, February 25th. The company reported $1.19 EPS for the quarter, missing the consensus estimate of $1.23 by ($0.04). The company had revenue of $3.19 billion during the quarter, compared to analysts’ expectations of $3.25 billion. Henry Schein had a return on equity of 12.90% and a net margin of 2.51%. The company’s quarterly revenue was up 5.8% on a year-over-year basis. During the same period in the prior year, the business earned $0.66 EPS. On average, sell-side analysts expect that Henry Schein, Inc. will post 4.74 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on HSIC shares. Wells Fargo & Company started coverage on Henry Schein in a research report on Friday, February 14th. They set an “equal weight” rating and a $80.00 price target on the stock. UBS Group decreased their price target on shares of Henry Schein from $83.00 to $80.00 and set a “neutral” rating for the company in a research note on Wednesday, February 26th. Barrington Research restated an “outperform” rating and issued a $90.00 price objective on shares of Henry Schein in a report on Wednesday, February 26th. Jefferies Financial Group boosted their price target on Henry Schein from $77.00 to $80.00 and gave the stock a “hold” rating in a research report on Thursday, January 23rd. Finally, Mizuho started coverage on shares of Henry Schein in a research note on Wednesday, December 4th. They issued a “neutral” rating and a $75.00 price target on the stock. Six research analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Henry Schein currently has an average rating of “Moderate Buy” and an average target price of $81.10.

Henry Schein Profile

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.